Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlying mechanisms and uncovers a promising countermeasure.

Using next-generation sequencing, the UPSeq test assesses 15 biomarkers to find aggressive prostate cancer that can be missed by biopsies or imaging tests.

The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.

Urine test found to be extremely accurate at detecting aggressive prostate cancer with few false negatives.

Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus.

The multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.

Multi-institution analysis identifies a new chromosomal abnormality linked to enzalutamide resistance.

University of Michigan research shows the direct correlation between systemic racism and racial health disparities in the United States.

Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.

Antiandrogen treatment is associated with heart and neurological problems and didn’t increase survival for this group of men, a U-M analysis finds.

An international team of radiation oncologists are helping to protect patients and providers and conserve protective equipment for frontline health care workers during the COVID-19 pandemic.

Prostate cancer patients can now pursue healthy sex lives/sexual relationships after surgery

Researchers characterize three ways in which the gene FOXA1 mutates to trigger prostate cancer.

The largest study of its kind finds societal factors and access to quality care, rather than genetics, underlies higher prostate cancer mortality rates for black men.

A new study finds that U-M-designed compounds led to significantly smaller, slower-growing tumors.